ETH
BIOTW

Exos TFP Holdings’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Exos TFP Holdings’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed – – 637
2022
Q3 		$0 Buy
+100
New +$6 ﹤0.01% 500

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Exos TFP Holdings's BIOTW Position: Q4 2022 in Review

Exos TFP Holdings sold out of Biotech Acquisition Company Warrant (BIOTW) in Q4 2022, closing a stake of 100 shares.

Exos TFP Holdings first reported a position in BIOTW in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 48 funds tracked by Wall St. Rank hold BIOTW as of Q4 2022.

  • Exos TFP Holdings reported no remaining Biotech Acquisition Company Warrant position as of Q4 2022 after selling out during the quarter.
  • Exos TFP Holdings sold 100 Biotech Acquisition Company Warrant shares in Q4 2022.
  • Exos TFP Holdings first reported a position in Biotech Acquisition Company Warrant in Q3 2022 and held it in 1 quarter.
  • Exos TFP Holdings's Biotech Acquisition Company Warrant position peaked at $0 in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q4 2022.

Based on Exos TFP Holdings's 13F filing for Q4 2022, filed 10 Feb 2023.